🟢 EIQ.XA is trading 32.93% up today on U.S. leadership appointments for FDA and commercial expansion

EIQ.XA is trading at A$1.65 (+32.93%) after announcing key U.S.-focused leadership appointments to drive FDA regulatory progress and commercial expansion.

• The company appointed Matthew Dodds as CFO and added senior clinical leadership to spearhead its U.S. regulatory and growth plans.
• The surge appears company-specific, as the stock significantly outperformed broader indices which remained flat during the session.